Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib with Cisplatin and 5-FU in Advanced Gastric/GEJ Cancer
NCT01743365Phase 2Completed
- Sponsor
- HeCOG
- Start
- Feb 2013
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by HeCOG. Primary endpoint: Objective Response Rate at 6 months. Started Feb 2013; status: completed.
02
Drugs
afatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01743365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743365.